JACOBUS PHARMA CO INC has a total of 17 patent applications. Its first patent ever was published in 1992. It filed its patents most often in United States, EPO (European Patent Office) and Poland. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and machines are CHARTERHOUSE THERAPEUTICS LTD, SINDELAR KAREL and PROTERRA AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Poland | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 | |
#6 | Canada | 1 | |
#7 | China | 1 | |
#8 | Egypt | 1 | |
#9 | Hungary | 1 | |
#10 | Norway | 1 | |
#11 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Machines | |
#4 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Canfield Craig | 10 |
#2 | Lewis Neil | 9 |
#3 | Jacobus David | 9 |
#4 | Jacobus David P | 5 |
#5 | Jensen Norman P | 3 |
#6 | Terpinski Jacek | 2 |
#7 | Lewis Neil J | 2 |
#8 | Patel Vithal | 1 |
#9 | Jacobus D P | 1 |
#10 | Canfield C | 1 |
Publication | Filing date | Title |
---|---|---|
US6551614B2 | Antimalarial N,N′-substituted biguanides derived from hydroxylamines | |
US5658952A | 1-[4-(4'-sulfanilyl)phenyl]urea and derivatives for the treatment of Leishmaniasis | |
WO9602531A1 | Water soluble orally effective iron chelator | |
US5322858A | N,N'-substituted imidodicarbonimidic diamides derived from hydroxylamines |